RGEN: Q3 orders and recovering modalities set up a stronger 2027 growth outlook
Repligen Corporation (RGEN) faced headwinds in 2026 for its filtration and equipment sectors, but strong Q3 orders suggest a potential capital expenditure rebound in 2027. The company's growth outlook is further bolstered by BioLife synergies, protein growth, and the recovery of new modalities, with a target to outgrow the market by at least five points in 2027. This information is based on the Repligen Corporation Jefferies Global Healthcare Conference Audio Transcript from November 18, 2026.
ETF investissant dans des actions Repligen Corporation
This article lists various Exchange Traded Funds (ETFs) that hold shares of Repligen Corporation (RGN). It provides details for each ETF, including market value, weight of RGN shares, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year total NAV return. The information aims to help investors identify funds with RGN exposure, offering opportunities with reduced risk.
Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Matters
Repligen's stock (RGEN) is currently trading at US$162.78, reflecting a mixed performance over recent years, with a 40.6% decline over the past 5 years. A Discounted Cash Flow (DCF) analysis suggests the current share price is fairly valued, aligning with projected cash flow growth over the next decade. Analysts emphasize successful execution of the BioLife integration and Asia Pacific expansion as key factors for future valuation shifts.
Understanding Momentum Shifts in (RGEN)
This report analyzes Repligen Corporation (NASDAQ: RGEN), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details three AI-generated trading strategies: a long position trading strategy, a breakout momentum strategy, and a tactical short risk hedging strategy, each with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis, showing support and resistance levels.
Is Repligen (RGEN) Fully Priced After Its $1B Notes Deal?
Repligen (RGEN) recently issued US$1.0 billion in convertible senior notes, sparking questions about its valuation. Despite a 14.7% gain over the past year, the stock is down 38.4% over five years. A Discounted Cash Flow (DCF) analysis suggests the current share price is broadly in line with its intrinsic value, factoring in projected future cash flows and the new financing's potential impact on growth and buybacks.
How Investors Are Reacting To Repligen (RGEN) Impairment Charges And Quarterly Loss
Repligen Corporation reported a Q3 2026 net loss of US$38.43 million, including US$41.24 million in intangible asset impairment charges, despite higher revenue. This shift from profit to loss, coupled with new convertible senior notes, emphasizes the need for strong operational execution and disciplined capital allocation. Investors are now focused on order quality, pricing power, and product mix, as the company works to convert bioprocessing demand into recurring revenue.
In London, Repligen's CEO will join an analyst-led discussion on Nov. 18.
Repligen (NASDAQ:RGEN) announced that its President and CEO, Olivier Loeillot, will participate in an analyst-led discussion at the Jefferies Global Healthcare Conference in London on November 18, 2026, at 2:00 p.m. GMT. A live webcast of the event will be available on Repligen's Investor Relations website, with a replay accessible for a limited time afterward. The company, a global bioprocessing firm, develops and commercializes innovative technologies for manufacturing biologic drugs.
Repligen Corp (RGEN)
This article provides key financial metrics and investor information for Repligen Corp (RGEN). As of November 18, 2026, RGEN's stock price was $171.11, showing a daily increase of 5.51% (+8.93 today), despite a slight dip of -3.02% (-5.32) at 7:30 PM UTC. The company has a market cap of $10.9B and a forward P/E ratio of 64.5x, with annual revenue of $806M and a year-over-year growth of 10.9%.
Repligen Corporation to Present at Jefferies Global Healthcare Conference
Repligen Corporation (NASDAQ:RGEN) announced its participation in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and CEO, will lead an analyst discussion on November 18th at 2:00 p.m. GMT, with a live webcast available on Repligen's Investor Relations website.
Repligen (RGEN) Stock Looks Reasonable Despite Its 35% Five Year Fall
Repligen (RGEN) has experienced mixed share-price performance, with a gain over the past year but a 34.7% decline over five years. Despite this, a Discounted Cash Flow (DCF) model suggests the current stock price of US$178.27 is broadly in line with its estimated intrinsic value, assuming a meaningful ramp-up in future cash generation. The company's recent US$1.0b convertible note issue, partly for share repurchases and acquisitions, is seen as potentially lifting per-share cash flow if managed carefully.
Repligen (RGEN) Stock Price, Chart & Analysis
This article provides a comprehensive analysis of Repligen (RGEN) stock, including its current price, market capitalization, and key financial figures. It examines the company's quality score, growth metrics, and valuation based on various financial yardsticks and analyst forecasts. The report also includes "What if" scenarios for future price performance under different growth and margin assumptions.
Repligen 'Very Confident' in Filtration Business Returning to Historical Growth Rates Next Year, RBC Says
RBC Capital Markets reiterated its Outperform rating on Repligen, noting the company's confidence in its filtration business returning to historical growth rates next year. This optimism is based on a strong demand environment and ongoing capacity expansion, which RBC believes positions Repligen for significant recovery and growth.
Weekly Recap: Higher 2026 guidance and phased manufacturing restructuring
Repligen Corporation (NASDAQ:RGEN) has increased its 2026 revenue forecast following strong Q3 growth and the acquisition of BioLife Solutions. The company also initiated a phased restructuring of its manufacturing operations, which is expected to continue through 2027. RBC reaffirmed an Outperform rating with a $200 target, citing robust demand for equipment and consumables.
Stifel reiterates Buy on Repligen stock, keeps $207 target By Investing.com
Stifel maintained its Buy rating on Repligen Corporation (NASDAQ:RGEN) and set a price target of $207, citing potential upside from the Biolife acquisition and favorable margin synergies. Despite some revenue recognition challenges in its base business, the firm anticipates strong filtration re-acceleration in 2027 and robust demand in Process Analytics, expecting Repligen to achieve 15% organic growth. This outlook follows Repligen's strong Q3 2026 earnings, which exceeded expectations, driven by significant growth in its Chromatography and Proteins segments.
Revenue grows 10.9%, yet Repligen (RGEN) swings from profit to a Q3 loss.
Repligen Corporation (RGEN) reported a Q3 2026 net loss of $38.4 million, a significant swing from a net income of $14.9 million in Q3 2025, despite a 10.9% revenue increase to $209.3 million. The loss was primarily due to a $41.2 million impairment charge on developed-technology intangible assets. The company also announced the completion of its BioLife acquisition for approximately $1.9 billion and plans to issue $1.0 billion in convertible notes in November 2026.
Form 8K Repligen Corporation For: 30 October By Investing.com
This article announces that Repligen Corporation filed a Form 8K on October 30. The brief report from Investing.com includes a Reuters image and notes a 6.20% decrease in Repligen's stock (RGEN) price. The content primarily serves as a notification of the filing rather than an in-depth analysis.
Repligen 3Q 2026: Revenue $209.3M, EPS $(0.68) — 10-Q Summary
Repligen reported third-quarter 2026 revenue of $209.3M, a 10.9% increase year over year, but recorded a net loss of $38.4M, resulting in diluted EPS of $(0.68). The loss included a $41.2M intangible asset impairment charge. The company saw product revenue growth across all franchises, particularly in Europe, and made strategic acquisitions while undergoing a manufacturing restructuring.
Form 8K Repligen Corporation For: 30 October By Investing.com
This article reports on Repligen Corporation's Form 8K filing for October 30th. Form 8K is a crucial document that U.S. public companies file with the SEC to announce major events that shareholders should know about. The filing provides important information regarding the company's recent activities.
Repligen Earnings: Strong Growth and Margin Expansion Despite Filtration and Inflation Headwinds
Repligen reported strong financial results, achieving 12.5% year-on-year organic revenue growth and a 1.9 percentage point expansion in its adjusted EBITDA margin. The company's management now anticipates a full-year adjusted EBITDA margin of 21%, which is at the high end of its previous guidance. This performance highlights the company's ability to grow and improve profitability despite challenges in filtration and inflationary pressures.
Canaccord reiterates Hold on Repligen stock after Q3 beat By Investing.com
Canaccord Genuity has reiterated its Hold rating and $180 price target for Repligen Corp. (NASDAQ:RGEN) stock after the company's Q3 2026 results exceeded estimates. Revenue growth was driven by strong performance in the Chromatography and Proteins segments, with China revenue and consumables also showing significant expansion. Despite a decline in the Filtration segment, Repligen raised its 2026 revenue guidance, reflecting strong performance and the BioLife Solutions acquisition, indicating the company is growing above the bioprocessing market.
Repligen Posts Record Q3 Revenue, Narrows 2026 Organic Growth Outlook
Repligen Corp. reported record third-quarter 2026 revenue of $209 million, an 11% year-over-year increase, driven by strong biopharma demand for chromatography and proteins, offsetting filtration weakness. The company raised its full-year 2026 revenue outlook to $844 million–$852 million following the BioLife Solutions acquisition and narrowed its organic growth forecast to 12%–13%. Adjusted diluted EPS grew 15% to $0.53, supported by operating-margin expansion.
Repligen Q3 2026 Earnings Call Transcript
Repligen (NASDAQ: RGEN) reported record Q3 2026 revenue of $209 million, an organic growth of 12.5%, and expanded adjusted operating margins by 170 basis points year-over-year. The company increased its 2026 guidance, expecting a $24 million revenue contribution from the recent BioLife acquisition in Q4, and projects at least 25% top-line growth for 2027. Repligen saw significant growth in chromatography and proteins, with strong order activity for capital equipment, despite a decline in filtration revenue due to timing of system orders.
RGEN: Q3 growth lifted FY26 guidance as BioLife expanded the cell therapy portfolio
Repligen Corporation (RGEN) reported an 11% reported and 12.5% organic revenue increase in Q3, with adjusted operating income and EPS also rising year-over-year. The company raised its FY26 guidance, incorporating BioLife from its October closing date, although GAAP results included a $41.2 million intangible impairment charge. This positive Q3 performance and the BioLife expansion contributed to the updated financial outlook.
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation announced strong Q3 2026 financial results with revenue of $209 million, an 11% year-over-year increase, driven by 12.5% organic growth. The company successfully completed the acquisition of BioLife Solutions, strengthening its position in the cell therapy market, and subsequently raised its full-year 2026 revenue guidance to $844-$852 million. These achievements highlight Repligen's expanding portfolio and commitment to strategic market development, including the opening of a new training center in Seoul, South Korea.
REPLIGEN ($RGEN) Releases Q3 2026 Earnings
REPLIGEN ($RGEN) announced its Q3 2026 earnings, reporting $0.53 per share, surpassing analyst estimates, but revenue of $209.31 million missed expectations. Insider trading activity showed sales by executives, while institutional investors had mixed movements in their holdings. Analysts have issued "Overweight" ratings and a median price target of $160.0 for the stock.
Repligen Reports Q3 Revenue Growth, Raises 2026 Guidance
Repligen reported a strong third quarter in 2026, with revenue up 11% year over year to $209.3 million, driven by organic growth and demand in consumables and services. The company completed its acquisition of BioLife Solutions in October, expanding into cell therapy, and subsequently raised its full-year 2026 revenue guidance to $844 million–$852 million. Despite a GAAP net loss due to an intangible asset impairment, adjusted diluted EPS increased to $0.53.
Repligen (RGEN) Q3 earnings report preview: what to look for
Repligen Corporation (RGEN) is set to report its Q3 earnings before market hours on Tuesday. The market anticipates a 9.6% year-on-year revenue growth, a slowdown from the previous year, though analysts have largely maintained their estimates. While the life sciences tools & services segment has seen positive investor sentiment, Repligen's shares are down 8.8% over the last month, heading into earnings with an average analyst price target of $201.45.
Repligen Corporation (R2GE34.SA) cash flow
This article provides a detailed look into Repligen Corporation's cash flow, including operating, investing, and financing cash flows from 2022 to 2025. It presents both annual and quarterly data for key financial metrics such as end cash position, income tax paid, interest paid, and free cash flow. The financial statements are scheduled for an update on November 9, 2026, promising a new layout with more detail.
Repligen Corporation Estimates – NASDAQ:RGEN
This article provides an overview of Repligen Corporation (NASDAQ: RGEN) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements, allowing comparison of actual results with average, high, and low estimates, and visualization of trends over time. The platform includes sections for income statement, balance sheet, cash flow, and valuation metrics, for both annual and quarterly data.
Repligen Corporation Bonds — Corporate Bond Rates
This article provides a list of Repligen Corporation bonds, sorted by yield to worst, to help investors find stable investment opportunities. It details a specific bond (RGEN5964422) with a 1.0% coupon, maturing on December 15, 2028, and an outstanding amount of $600 million USD. The information aims to guide investors interested in corporate debt securities, often chosen for their stability during volatile market conditions.
Las ETF que invierten en acciones de Repligen Corporation
This article lists various Exchange Traded Funds (ETFs) that include shares of Repligen Corporation (RGN) in their portfolios. The ETFs are presented with details such as market value, weight of RGN stock, issuer, management style, expense ratio, assets under management (AUM), price, and total return. The information aims to facilitate investment in RGN by showcasing diversified opportunities with potentially lower risk through these funds.
RGEN Maintained by Canaccord Genuity -- Price Target Raised to $180
Canaccord Genuity has maintained its Hold rating for Repligen (RGEN) while increasing the price target from $145.00 to $180.00. The stock is currently deemed 3.0% undervalued with a GF Value™ of $180.88, despite a high P/E ratio, and holds a strong GF Score™ of 86/100, though insider selling has been significant.
Repligen Corp (RGEN) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 85/100
Repligen Corp (RGEN) stock increased by 3.4%, but GuruFocus's GF Value™ indicates it is 1.9% overvalued at $184.17 compared to its intrinsic value estimate of $180.67. Despite a strong GF Score™ of 85/100 and positive sentiment from gurus, insider activity shows significant selling, raising concerns about its current high valuation and P/E ratio. Investors are advised to exercise caution due to the overvaluation and mixed signals from insider transactions.
Repligen Corporation (RGEN) Stock Forecasts
This article provides a stock forecast for Repligen Corporation (RGEN), a global life sciences company specializing in bioprocessing equipment. It highlights an "Upgrade" prompt for premium research reports, including an Argus report from October 14, 2026, which mentions the company's current price and a call to download the full report. The article also lists related reports for other companies and their stock price movements.
Repligen to Report Third Quarter 2026 Financial Results
Repligen Corporation announced it will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The company will issue a press release before market open and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the period ended September 30, 2026. A webcast of the call will be available on the Investor Relations section of Repligen’s website.
A company behind systems used to make biological drugs will discuss results Oct. 27. Repligen's call starts at 8 a.m.
Repligen (RGEN) announced it will report its third-quarter 2026 financial results before the market opens on October 27, 2026. A conference call and webcast will be held at 8:00 a.m. ET on the same day to discuss business updates and results for the period ending September 30, 2026. The company specializes in bioprocessing technologies for manufacturing biological drugs.
Repligen to Report Third Quarter 2026 Financial Results
Repligen Corporation announced it will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The company will issue a press release before market open and host a conference call at 8:00 a.m. ET to discuss updates and results for the period ending September 30, 2026. A webcast of the call will be available on the Investor Relations section of their website.
Repligen to Report Third Quarter 2026 Financial Results
Repligen Corporation announced it will report its third quarter 2026 financial results on Tuesday, October 27, 2026. The company will issue a press release before market open and host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the period ended September 30, 2026. A webcast of the call will also be available on the Investor Relations section of their website.
Weekly Recap: BioLife cash-and-stock deal and Q3 2026 outlook details
Repligen Corporation (NASDAQ:RGEN) has finalized its acquisition of BioLife, integrating the CryoStor biopreservation line into its operations. The deal involved a payment of $11.25 cash plus 0.1442 RGEN shares for each BioLife share. Repligen plans to elaborate on the expected impact of this acquisition on its 2026 financial outlook during its Q3 2026 earnings call.
Form 144 REPLIGEN CORP For: 12 October By Investing.com
This Investing.com article reports on the filing of Form 144 for Repligen Corp (RGEN) on October 12. Form 144 is a notice of the intent to sell restricted securities. The article provides only this detail, with no further information about the transaction itself.
RGEN5964422 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Repligen Corporation's RGEN5964422 bond. It outlines key facts such as the issuer, issue and maturity dates, face value, and minimum denomination. The profile also details interest payment information, including the 1.00% semi-annual fixed coupon rate and upcoming payout schedule, as well as the bond's redemption details and outstanding amount.
Repligen Corp (BSP:R2GE34) Stock Holders - Institutional & Insider Ownership
This article provides an overview of Repligen Corp's (BSP:R2GE34) institutional and insider ownership. It details key financial metrics such as market cap, P/E ratio, and shares outstanding, while also offering historical data and definitions related to ownership types. The content emphasizes the importance of analyzing institutional and insider holdings when evaluating a company.
Form 4 Repligen Corporation For: 9 October By Investing.com
This article reports a Form 4 filing for Repligen Corporation, related to an event on October 9th. It provides minimal detail, primarily serving as a placeholder announcement for the regulatory filing. The content also includes market data, news headlines, and promotional material from Investing.com.
Form 4 Repligen Corporation For: 9 October By Investing.com
This article reports on a Form 4 filing for Repligen Corporation (RGEN) on October 9th. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The article indicates a 6.13% increase for RGEN, suggesting notable insider activity.
Form 4 Repligen Corporation For: 9 October By Investing.com
The article reports on a Form 4 filing for Repligen Corporation on October 9th. It is a brief announcement with no further details provided in the main text other than the company name and filing date. The surrounding content consists mostly of financial market data, indices, commodity prices, and news headlines.
Roderick De Greef Fully Exits BioLife Solutions Following Repligen Merger on October 6, 2026
Roderick De Greef, CEO and Director of BioLife Solutions Inc., fully exited his stake in the company following its merger with Repligen Corporation on October 6, 2026. The merger involved the conversion of all BioLife common stock into cash and Repligen shares, reducing De Greef's direct ownership to zero. Key transactions included the vesting of restricted stock grants, shares withheld for tax purposes, and the sale of remaining shares as part of the merger agreement.
Joydeep Goswami Sells 53,156 BioLife Shares Following Repligen Merger Completion
Joydeep Goswami, a director at BioLife Solutions, sold 53,156 shares of BioLife Solutions common stock on October 6, 2026. This transaction occurred due to the completion of the merger between BioLife Solutions and Repligen Corporation. Following the sale, Goswami holds zero shares of BioLife Solutions.
A 700-share stock grant joins options with a $174.86 exercise price for Repligen (RGEN)’s chief product officer.
Repligen Corp.'s Chief Product Officer, Brian Robb Douglass, was awarded 700 restricted stock units (RSUs) and options to purchase 675 common shares on October 6, 2026. The RSUs will vest in equal annual installments over three years, while the stock options, with an exercise price of $174.86 per share, will vest annually from October 6, 2027, through October 6, 2029, and expire in 2036. Following this award, Douglass directly holds 8,685 shares of common stock.
One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake.
FMR LLC and Abigail P. Johnson each reported a 13.0% beneficial ownership stake in Repligen Corp. (RGEN) as of September 30, 2026, totaling 7,361,317.84 shares. While FMR LLC holds sole voting power over a significant portion of these shares, Abigail P. Johnson reported no sole voting power, despite maintaining the same beneficial and sole dispositive power. The filing indicates this is a passive investment not intended to influence control of the issuer.
Repligen Insider Sold Shares Worth $1,036,654, According to a Recent SEC Filing
Repligen Director and CEO, Olivier Loeillot, sold 5,535 shares of the company on October 05, 2026, for a total value of $1,036,654. This information is based on a recent SEC filing. The article is a premium MT Newswires piece, requiring a subscription to view the full details.